The introduction of a second vaccine against the epidemic of Ebola virus disease began Thursday in Goma in eastern Democratic Republic of Congo, said the NGO Doctors Without Borders (MSF) to AFP.
The use of the vaccine produced by Janssen Pharmaceuticals for Johnson & Johnson « will target 50,000 people over a period of four months, » says MSF, responsible for its implementation in two centers in Goma.
More than 250,000 people have already received the dose of a first vaccine since the beginning of the epidemic in the region in August 2018.
At 07:00 GMT, about fifteen people were given an injection in one of the two centers of MSF Majengo district, according to a spokesman for the NGO.
« After receiving the first dose of the vaccine, participants will be asked to come back two months later for a second injection to complete the vaccination protocol, » MSF said in a statement.
The preliminary phase « will be used to verify the success of the two-dose vaccination in a city of one million inhabitants, in a region with a very mobile population and where there have been cases in the past ».
At least two cases of haemorrhagic fever were recorded in July-August in Goma, the provincial capital of North Kivu on the Rwandan border.
But the epicenter is 350 km north of Goma, in the Beni-Butembo region, and marginally in Ituri province.
Declared on August 1, 2018, the 10th epidemic of hemorrhagic fever on Congolese soil killed 2,193 people, for 1,067 cures.